Clinical characteristics at baseline and follow-up
| Overall cohort | N | Baseline | FU | P value |
| Mean (SD) | Mean (SD) | |||
| QUIP-RS total | 55 | 15.4 (13.1) | 14.6 (13.5) | 0.585 |
| PDQ-8 SI | 51 | 29.3 (17.4) | 21.2 (14.3) | 0.005 |
| NMSS total | 55 | 53.8 (29.9) | 35.5 (25.4) | <0.001 |
| UPDRS | ||||
| Part-II | 54 | 11.7 (6.7) | 7.7 (5.4) | <0.001 |
| Part-III | 50 | 21.3 (10.5) | 18.3 (11.0) | 0.199 |
| Part-IV | 54 | 6.7 (3.7) | 3.6 (3.2) | <0.001 |
| LEDD total | 55 | 1102.4 (444.5) | 578.1 (317.3) | <0.001 |
| LEDD-DA | 54 | 248.1 (162.7) | 164.8 (127.1) | <0.001 |
| Patients with clinically relevant preoperative impulsive and compulsive behaviour | ||||
| QUIP-RS total | 14 | 30.5 (10.7) | 24.1 (14.0) | 0.044 |
| PDQ-8 SI | 14 | 36.2 (12.4) | 24.8 (11.0) | 0.054 |
| NMSS total | 14 | 74.7 (37.9) | 43.3 (26.2) | 0.016 |
| UPDRS | ||||
| Part-II | 13 | 12.5 (8.7) | 7.7 (5.6) | n.s. |
| Part-III | 13 | 20.6 (14.7) | 15.8 (7.8) | n.s. |
| Part-IV | 13 | 8.7 (3.2) | 3.8 (3.8) | 0.058 |
| LEDD total | 14 | 1178.1 (519.6) | 576.4 (316.2) | 0.004 |
| LEDD-DA | 14 | 280.8 (101.8) | 157.5 (101.0) | 0.010 |
Wilcoxon signed-rank or t-tests, when parametric test criteria were fulfilled, between baseline and 6-month follow-up to analyse within-group changes of outcome parameters.
Bold font highlights significant results.
Multiple comparisons (two groups) were corrected with the Bonferroni method.
FU, follow-up; LEDD, levodopa equivalent daily dose; LEDD-DA, LEDD of dopamine agonists; NMSS, Non-Motor Symptom Scale; n.s., not significant; PDQ-8 SI, Parkinson’s Disease Questionnaire-8 Summary Index; QUIP-RS, Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease Rating Scale; UPDRS, Unified Parkinson’s Disease Rating Scale.